888-430-5470
  • Facebook
  • Twitter
  • Google
  • Facebook
  • Twitter
  • Google
Drug Outlook
  • Drugs & Devices
    • Actos
    • Benicar
    • Da Vinci Robots
    • Essure
    • Granuflo
    • Hip Implants
    • INFUSE® Bone Graft
    • IVC Filters
    • Physiomesh
    • Power Morcellator
    • Pradaxa
    • Risperdal
    • SGLT2 Inhibitors
    • Talcum Powder
    • Testosterone Therapy
    • Transvaginal Mesh
    • Viagra
    • Xarelto
    • Zofran
  • Manufacturers
    • AbbVie & Abbott
    • Boehringer Ingelheim
    • Eli Lilly
    • GlaxoSmithKline
    • Takeda Pharma
  • Current Lawsuits
    • Case Evaluation
  • News
  • DrugHub©
Select Page
  • Drugs & Devices
    • Actos
    • Benicar
    • Da Vinci Robots
    • Essure
    • Granuflo
    • Hip Implants
    • INFUSE® Bone Graft
    • IVC Filters
    • Physiomesh
    • Power Morcellator
    • Pradaxa
    • Risperdal
    • SGLT2 Inhibitors
    • Talcum Powder
    • Testosterone Therapy
    • Transvaginal Mesh
    • Viagra
    • Xarelto
    • Zofran
  • Manufacturers
    • AbbVie & Abbott
    • Boehringer Ingelheim
    • Eli Lilly
    • GlaxoSmithKline
    • Takeda Pharma
  • Current Lawsuits
    • Case Evaluation
  • News
  • DrugHub©

Million-Dollar Drugs: Gene Therapy No One Can Afford

by Mooslet Writing Services | Jun 23, 2016 | Clinical Trials

What is the value of being able to see? If it costs a half a million dollars per eye to cure genetic blindness, would you do it? Now, let’s make the scenario more complex. Let’s say a cure for hemophilia B would run you $4 million upfront. Would you instead agree to...

Sharing Pharmaceutical Data Could Save Lives and Dollars

by Mooslet Writing Services | Apr 21, 2016 | Clinical Trials

When medical research is performed, the results are published in a peer-reviewed medical journal – such as the Journal of the American Medical Association (JAMA) or the New England Journal of Medicine (NEJM). Publishing their findings is how scientists...

Janssen Suspends FAAH Inhibitor Trial

by Mooslet Writing Services | Feb 2, 2016 | Clinical Trials

In a proactive move, Janssen Pharmaceuticals announced on January 17 that they were voluntarily halting clinical trials of the experimental drug JNJ-42165279. According to Forbes, the experimental drug being tested is in a similar class of drugs which recently caused...

Recent Posts

  • Price-Gouging for Profit: The Rise and Fall of Valeant
  • Drug Wholesalers Settle Opioid Lawsuit
  • Lawmakers Fight To Improve Access to Generic Drugs
  • Million-Dollar Drugs: Gene Therapy No One Can Afford
  • WHO Endorses Olympics Despite Zika Virus

Recent Comments

  • Namaste927 on Lioresal
  • Mietzekatze on Maxzide
  • Jack on Zyloprim

Archives

  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • October 2015

Categories

  • Big Pharma Business
  • Big Pharma Lawsuits
  • Clinical Trials
  • Consumer Healthcare
  • FDA
  • Prescription Drugs
  • Uncategorized

Meta

  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org

THIS IS A PAID ATTORNEY/ADVOCATE ADVERTISEMENT. This website is a group advertisement and a fee is paid for by participating attorneys and advocates. The site is not an attorney referral service or prepaid legal services plan. The information provided by Drug Outlook is not a substitute for professional medical advice, diagnosis or treatment. The views and opinions expressed on the site do not necessarily represent those of Drug Outlook. This website does not make any representation to the qualifications, expertise or credentials of participating attorneys/advocates and does not represent that quality is better than services performed by other attorneys/advocates. Any information you submit to this website may not be protected by attorney-client privilege. An automated matching system will match each request with a member attorney/advocate representing the specific geography.

If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of "Fair Use" and legitimately infringes on yours or your client's copyright, we may be contacted concerning copyright matters at: webmaster@drugoutlook.com

©2015 DrugOutlook.com. View our Terms of Use or Privacy Policy.